A non-opioid designer molecule for treating chronic neuropathic pain by calming hyperactive pain-sensing neurons in the peripheral nervous system has had promising results in a preclinical study ...

Colorado is coming closer to universal access to overdose-reversing medication as residents snap up an over-the-counter version and hospitals offer it to more patients. In the past two decades, there ...

On Jun 10, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly’s LLY Alzheimer's disease drug, donanemab. Eli ...

Please provide your email address to receive an email when new articles are posted on . The FDA panel voted 11-0 in favor of donanemab as an effective treatment for early-stage Alzheimer’s. The ...

A new treatment for amyotrophic lateral sclerosis, or ALS, has been approved by the US Food and Drug Administration. The FDA announced approval of Relyvrio, developed by Amylyx Pharmaceuticals, on ...

Please provide your email address to receive an email when new articles are posted on . The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously that tofersen, an ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

The FDA issued briefing documents on Biogen’s BIIB Alzheimer’s disease (“AD”) drug Leqembi (lecanemab) for the upcoming Peripheral and Central Nervous System Drugs Advisory Committee (“PCNSDAC”) ...

The addictive properties of opioids and the lives shattered by their misuse and overprescription are heavily chronicled chapters of the early 21st century. For over 2 decades, scientists in academia ...

Tofersen’s development is progressing in fits and starts. That was evident at the U.S. FDA’s March 22 meeting of the Peripheral and Central Nervous System Drugs Advisory Committee, which unanimously ...

A Food and Drug Administration advisory panel voted Wednesday to recommend an experimental drug for patients with ALS, a reversal from its decision in March and a victory for advocacy groups pushing ...

A federal advisory panel on Monday voted in favor of recommending Eli Lilly’s new drug that is under consideration for its potential to slow the progression of Alzheimer’s disease. The Food and Drug ...